Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2

Background. Patients with chronic cardiorenal syndrome type 2 (T2-CRS) who qualify for resynchronization therapy (CRT) are exposed perioperatively to potentially nephrotoxic factors including contrast agents and blood loss. Methods. The objective of this prospective interventional study was to asses...

Full description

Bibliographic Details
Main Authors: Agnieszka Gala-Błądzińska, Janusz Romanek, Danuta Mazur, Tomasz Stepek, Marcin Braun, Piotr Szafarz, Marcin Chlebuś, Andrzej Przybylski
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Cardiology Research and Practice
Online Access:http://dx.doi.org/10.1155/2020/2727108
id doaj-6e9130e1558848f2a3099fc03b847b9a
record_format Article
spelling doaj-6e9130e1558848f2a3099fc03b847b9a2020-11-25T02:30:47ZengHindawi LimitedCardiology Research and Practice2090-80162090-05972020-01-01202010.1155/2020/27271082727108Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2Agnieszka Gala-Błądzińska0Janusz Romanek1Danuta Mazur2Tomasz Stepek3Marcin Braun4Piotr Szafarz5Marcin Chlebuś6Andrzej Przybylski7Medical College of Rzeszów University, Institute of Medical Sciences, Rzeszów 35-310, PolandDepartment of Cardiology, St. Queen Jadwiga Clinical District Hospital No. 2 in Rzeszów, Rzeszów 35-301, PolandDepartment of Cardiology, St. Queen Jadwiga Clinical District Hospital No. 2 in Rzeszów, Rzeszów 35-301, PolandMedical College of Rzeszów University, Institute of Medical Sciences, Rzeszów 35-310, PolandDepartment of Pathology, Chair of Oncology, Medical University of Lodz, Łódź 90-647, PolandDepartment of Cardiology, St. Queen Jadwiga Clinical District Hospital No. 2 in Rzeszów, Rzeszów 35-301, PolandDepartment of Cardiology, St. Queen Jadwiga Clinical District Hospital No. 2 in Rzeszów, Rzeszów 35-301, PolandMedical College of Rzeszów University, Institute of Medical Sciences, Rzeszów 35-310, PolandBackground. Patients with chronic cardiorenal syndrome type 2 (T2-CRS) who qualify for resynchronization therapy (CRT) are exposed perioperatively to potentially nephrotoxic factors including contrast agents and blood loss. Methods. The objective of this prospective interventional study was to assess the effects of CRT on renal function in patients with T2-CRS within the first 48 hours following implantation. Initially, 76 patients (15% female; aged 69 ± 9.56 years) with heart failure (New York Heart Association classes II–IV), ejection fraction ≤ 35%, and QRS > 130 ms were included in the study. During CRT implantation, a nonionic contrast agent (72.2 ± 44.9 mL) was administered. Prior to and 48 hours following implantation, renal function was evaluated using the following serum biomarkers: creatinine (sCr), estimated glomerular filtration rate (using the Chronic Kidney Disease Epidemiology Collaboration equation [eGFRCKD-EPI]), and the electrolyte and urine biomarkers albumin (uAlb), albumin/creatinine ratio (UACR), and neutrophil gelatinase-associated lipocalin (uNGAL). Results. Before CRT, patients classified as NYHA class III or IV had higher uNGAL levels in comparison to uNGAL levels after CRT (43.63 ± 60.02 versus 16.63 ± 18.19; p=0.041). After CRT implantation, uAlb, UACR, and potassium levels were reduced (p<0.05), and uNGAL, sCr, and eGFRCKD-EPI were unchanged. The contrast medium volume did not correlate with the test biomarkers (p>0.05). Conclusions. In patients with T2-CRS, uNGAL is a biomarker of kidney injury that correlates with the NYHA classes. A stable uNGAL value before and after CRT implantation confirms the lack of risk of contrast-induced nephropathy. Reduced albuminuria and blood potassium are biomarkers of improving T2-CRS in the early post-CRT period.http://dx.doi.org/10.1155/2020/2727108
collection DOAJ
language English
format Article
sources DOAJ
author Agnieszka Gala-Błądzińska
Janusz Romanek
Danuta Mazur
Tomasz Stepek
Marcin Braun
Piotr Szafarz
Marcin Chlebuś
Andrzej Przybylski
spellingShingle Agnieszka Gala-Błądzińska
Janusz Romanek
Danuta Mazur
Tomasz Stepek
Marcin Braun
Piotr Szafarz
Marcin Chlebuś
Andrzej Przybylski
Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2
Cardiology Research and Practice
author_facet Agnieszka Gala-Błądzińska
Janusz Romanek
Danuta Mazur
Tomasz Stepek
Marcin Braun
Piotr Szafarz
Marcin Chlebuś
Andrzej Przybylski
author_sort Agnieszka Gala-Błądzińska
title Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2
title_short Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2
title_full Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2
title_fullStr Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2
title_full_unstemmed Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2
title_sort reduced albuminuria and potassemia indicate early renal repair processes after resynchronization therapy in cardiorenal syndrome type 2
publisher Hindawi Limited
series Cardiology Research and Practice
issn 2090-8016
2090-0597
publishDate 2020-01-01
description Background. Patients with chronic cardiorenal syndrome type 2 (T2-CRS) who qualify for resynchronization therapy (CRT) are exposed perioperatively to potentially nephrotoxic factors including contrast agents and blood loss. Methods. The objective of this prospective interventional study was to assess the effects of CRT on renal function in patients with T2-CRS within the first 48 hours following implantation. Initially, 76 patients (15% female; aged 69 ± 9.56 years) with heart failure (New York Heart Association classes II–IV), ejection fraction ≤ 35%, and QRS > 130 ms were included in the study. During CRT implantation, a nonionic contrast agent (72.2 ± 44.9 mL) was administered. Prior to and 48 hours following implantation, renal function was evaluated using the following serum biomarkers: creatinine (sCr), estimated glomerular filtration rate (using the Chronic Kidney Disease Epidemiology Collaboration equation [eGFRCKD-EPI]), and the electrolyte and urine biomarkers albumin (uAlb), albumin/creatinine ratio (UACR), and neutrophil gelatinase-associated lipocalin (uNGAL). Results. Before CRT, patients classified as NYHA class III or IV had higher uNGAL levels in comparison to uNGAL levels after CRT (43.63 ± 60.02 versus 16.63 ± 18.19; p=0.041). After CRT implantation, uAlb, UACR, and potassium levels were reduced (p<0.05), and uNGAL, sCr, and eGFRCKD-EPI were unchanged. The contrast medium volume did not correlate with the test biomarkers (p>0.05). Conclusions. In patients with T2-CRS, uNGAL is a biomarker of kidney injury that correlates with the NYHA classes. A stable uNGAL value before and after CRT implantation confirms the lack of risk of contrast-induced nephropathy. Reduced albuminuria and blood potassium are biomarkers of improving T2-CRS in the early post-CRT period.
url http://dx.doi.org/10.1155/2020/2727108
work_keys_str_mv AT agnieszkagalabładzinska reducedalbuminuriaandpotassemiaindicateearlyrenalrepairprocessesafterresynchronizationtherapyincardiorenalsyndrometype2
AT januszromanek reducedalbuminuriaandpotassemiaindicateearlyrenalrepairprocessesafterresynchronizationtherapyincardiorenalsyndrometype2
AT danutamazur reducedalbuminuriaandpotassemiaindicateearlyrenalrepairprocessesafterresynchronizationtherapyincardiorenalsyndrometype2
AT tomaszstepek reducedalbuminuriaandpotassemiaindicateearlyrenalrepairprocessesafterresynchronizationtherapyincardiorenalsyndrometype2
AT marcinbraun reducedalbuminuriaandpotassemiaindicateearlyrenalrepairprocessesafterresynchronizationtherapyincardiorenalsyndrometype2
AT piotrszafarz reducedalbuminuriaandpotassemiaindicateearlyrenalrepairprocessesafterresynchronizationtherapyincardiorenalsyndrometype2
AT marcinchlebus reducedalbuminuriaandpotassemiaindicateearlyrenalrepairprocessesafterresynchronizationtherapyincardiorenalsyndrometype2
AT andrzejprzybylski reducedalbuminuriaandpotassemiaindicateearlyrenalrepairprocessesafterresynchronizationtherapyincardiorenalsyndrometype2
_version_ 1715466305570603008